ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

ClinicalTrials.gov ID: NCT03686124

Public ClinicalTrials.gov record NCT03686124. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors

Study identification

NCT ID: NCT03686124
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Immatics US, Inc.; Industry
Enrollment: 375 participants

Conditions and interventions

Conditions

Interventions

IMA203 Product Biological
IMA203 product- flat dose Biological
IMA203CD8 Product Biological
IMADetect® Device
Nivolumab Drug

Biological · Device · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 13, 2019
Primary completion: Nov 30, 2028
Completion: May 31, 2032
Last update posted: May 12, 2026

2019 – 2032

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 11

Facility	City	State	ZIP	Site status
Stanford Cancer Institute	Stanford	California	94305	Recruiting
University of Colorado, Anschutz Medical Campus	Aurora	Colorado	80045	Recruiting
University of Miami Hospital and Clinics	Miami	Florida	33136	Recruiting
University of Chicago Medical Center	Chicago	Illinois	60637	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run	Columbus	Ohio	43026	Recruiting
University of Pennsylvania, Perelamn Center for Advanced Medicine	Philadelphia	Pennsylvania	19104	Recruiting
Thomas Jefferson University, Honickman Center	Philadelphia	Pennsylvania	19107	Recruiting
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Recruiting
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15232	Recruiting
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03686124, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 12, 2026 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03686124 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →